dc.contributor.author | Gungor-Ordueri, Nazli Ece | |
dc.contributor.author | Kuscu, Nilay | |
dc.contributor.author | Tasatargil, Arda | |
dc.contributor.author | Burgucu, Durmus | |
dc.contributor.author | Karacan, Meric | |
dc.contributor.author | Celik-Ozenci, Ciler | |
dc.date.accessioned | 2021-12-21T08:47:19Z | |
dc.date.available | 2021-12-21T08:47:19Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1734-1140 | |
dc.identifier.uri | https://doi.org/10.1016/j.pharep.2019.02.018 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2214 | |
dc.description.abstract | Background: Doxorubicin (DOX), is a chemotherapeutic agent, which evokes oxidative stress and cell apoptosis in testicular tissue. It is known that the activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), leading to apoptosis induced by D | |
dc.description.sponsorship | Turkish Scientific and Research Council (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [110S377]; Akdeniz University Research Foundation, Antalya, TurkeyAkdeniz University | |
dc.language.iso | English | |
dc.publisher | Polısh Acad Scıences Inst Pharmacology | |
dc.title | Doxorubicin-induced testicular damage is related to PARP-1 signaling molecules in mice | |
dc.type | Article | |
dc.relation.journal | Pharmacologıcal Reports | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 591 | |
dc.identifier.endpage | 602 | |
dc.identifier.volume | 71 | |
dc.identifier.doi | 10.1016/j.pharep.2019.02.018 | |
dc.relation.issue | 4 | |
dc.relation.volume | 71 | |